Mayo Clinic Picks 4DMedical (ASX:4DX), But It’s Still a 90-Day Trial

4DMedical (ASX:4DX) Adds Mayo Clinic, The Endorsement Is Huge, The Revenue Isn’t Yet

For 4DMedical investors, this is the kind of stock the market loves, but with names like this it is important to stay aware of how quickly momentum and speculative buying can take over. That looks to be part of what we are seeing in the share price today.

The company announced a partnership that is not financially material in the near term, but it is commercially and strategically important. Mayo Clinic, one of the top-ranked hospitals in the US, has entered an agreement to deploy 4DMedical’s CTVQ scans, the company’s proprietary imaging software.

This also marks the sixth leading US academic medical centre or clinic to adopt the technology since FDA approval, which adds further credibility to the rollout story.

It is important to keep the structure of the agreement in perspective. This is not a major revenue event today. The initial arrangement is a 90-day deployment designed to give Mayo clinicians hands-on experience with the technology before any longer-term commercial commitment is made.

What are the Best ASX Stocks to invest in right now?

Check our buy/sell tips

Who Is Mayo Clinic? Why Does This Matter?

Mayo Clinic is a very large and influential healthcare institution. As of 2024, it was generating close to US$20B in revenue, growing at roughly 10% per year, with a staff base of around 83,000 and a patient reach of 1.3 million people across 135 countries.

What matters is that Mayo is not a typical community hospital. Its model is built around handling some of the most difficult and unresolved medical cases from across the US and around the world. That makes it a natural fit for advanced diagnostic tools like CT:VQ, which can provide more detailed lung function insight than conventional imaging.

Mayo also operates more like a platform than a standalone hospital. It reaches around 56 million patient lives across four continents through its broader network of AI diagnostics, digital partnerships, and healthcare platforms.

In that sense, it is not just a treatment centre. It is one of the largest research, development, and clinical deployment hubs in global healthcare, which is why having Mayo engage with the technology carries real strategic weight.

Understanding the 90-Day Agreement

This is a pilot and evaluation deployment, not a commercial contract. Investors need to be clear-eyed about that, especially given the company added around A$1B in market cap on the back of the announcement, which is clearly speculative.

What this agreement does do is give Mayo clinicians the chance to use CT:VQ within real patient workflows and assess the technology in a practical clinical setting.

The investor’s takeaway for 4DX

We would caution investors against getting caught up in momentum and stock hype. The more important signal will come after the 90-day period, when we can see whether the evaluation turns into something more meaningful.

That said, Mayo Clinic is arguably the strongest institutional endorsement 4DMedical could get in US healthcare. It is one of the most respected hospitals in the world, and its involvement does help validate the importance of the technology.

With six institutions now adopting the platform and integrating it into clinical workflows, the strategic progress is real. The key now is whether that progress starts converting into commercial outcomes.